12th May 2025
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
10th April 2025
Curium enhances its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
2nd April 2025
Curium Announces Approval of Generic DTPA – Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
28th March 2025
Curium completes the acquisition of Monrol as part of its plan to significantly expand Lutetium-177 capacity and PET footprint
30th January 2025
Curium Expands European Supply of Iodine-131 Diagnostic Capsules with New Partnership Agreement with Izotop
28th January 2025
Curium Further Expands European Availability of Pylclari® – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients With Prostate Cancer
12th January 2025
Curium is attending these global congresses in 2025
19th November 2024
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
13th November 2024
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
1st October 2024
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
24th September 2024
Curium announces the official opening of its new Netherlands facility for the production of Lutetium-177 – a game changer therapy isotope for cancer patients worldwide
10th September 2024
Curium Announces Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – is now available in Spain
9th July 2024
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
17th June 2024
Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer
5th June 2024
Curium adds the Institut Laue–Langevin reactor to global irradiation portfolio to ensure continuous supply of Lutetium-177 benefit more than 100,000 cancer patients over the next 5 years
30th May 2024
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
29th May 2024
Curium extends irradiation partnership with NRG | Pallas in Netherlands for continuous supply of Lutetium-177 to treat 1,000s of cancer patients each year
6th May 2024
Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
23rd April 2024
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
8th April 2024